Jazz Pharmaceuticals to Present 21 Studies on Xywav at SLEEP 2026

Event summary

  • Jazz Pharmaceuticals will present 21 abstracts, including 11 late-breaking, at SLEEP 2026 from June 14-17, 2026.
  • Studies focus on Xywav's efficacy in narcolepsy and idiopathic hypersomnia, including sleep inertia and dosing patterns.
  • Key highlights include post-hoc analyses of the DUET study and real-world evidence from the LYRICAL study.
  • Xywav is the only FDA-approved treatment for idiopathic hypersomnia and has Orphan Drug Exclusivity.

The big picture

Jazz Pharmaceuticals' extensive data presentation at SLEEP 2026 underscores its commitment to advancing treatments for rare sleep disorders. The focus on real-world evidence and patient-reported outcomes aligns with broader industry trends toward personalized medicine and value-based healthcare. The strategic emphasis on reducing sodium intake and improving quality of life for patients with narcolepsy and idiopathic hypersomnia positions Xywav as a key player in the sleep disorder market.

What we're watching

Clinical Validation
Whether the comprehensive data from SLEEP 2026 will further solidify Xywav's position as a leading treatment for narcolepsy and idiopathic hypersomnia.
Regulatory Dynamics
How the FDA's Orphan Drug Exclusivity and the DEA's Schedule III designation will impact Xywav's market access and adoption.
Market Expansion
The pace at which Jazz Pharmaceuticals can leverage these findings to expand Xywav's use in pediatric and other underserved populations.